KarMMa-3: a phase 3, multicenter, randomized, open-label study to compare the efficacy and safety of bb2121 versus standard triplet regimens in subjects with relapsed and refractory multiple myeloma

Awarded By

  • Celgene

Contributors

Start/End

  • August 2019